Pulmonary re-biopsy in non–small-cell lung cancer (NSCLC) locally advanced or metastatic with EGFR-T790M resistance. Source: International Congress 2018 – Bronchoscopy and transthoracic ultrasound Year: 2018
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Endoscopical laser treatment in combined therapy non small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Biphosphonate, ibantronate improves analgesic therapy in non-small lung cancer (NSCLC) patients with bone metastases Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005
Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005
Extrathoracic 18-FDG-PET uptakes in non small cell lung cancer (NSCLC) preoperative staging Source: Eur Respir J 2007; 30: Suppl. 51, 430s Year: 2007
Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC). Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017
How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo). Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018
Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012